Hospital

The model also predicted prevalent cases of decompensated cirrhosis would more than triple, incident liver cancer cases would nearly double, and transplant almost quadruple.

Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors have transformed the treatment of hormone receptor-positive/HER2-negative breast cancer across metastatic and early-stage settings, with ongoing research exploring their potential in additional breast cancer subtypes, combination therapies, and aggressive disease scenarios.

Statin use is not associated with a change in incident chronic kidney disease (CKD) and estimated glomerular filtration rate in adult patients aged 65 and older.

Atopic dermatitis significantly impacts quality of life, and requires personalized management through trigger identification, skin barrier maintenance, and a range of topical, oral, and biologic therapies to reduce symptoms and prevent flare-ups.

The drug is a selective NaV1.8 pain signal inhibitor and is the first new class of medication to treat acute pain in over 20 years.

Digoxen is the active ingredient found in the foxglove plant and is commonly used to treat heart failure.

Lu-edotreotide (ITM-11; ITM) met its primary endpoint of prolonging progression-free survival (PFS).

Hypertrophic cardiomyopathy is caused by abnormal genes in the heart muscle, causing the left ventricle to become thicker and effecting blood flow.

Children and adults with cancer have differing immune system responses, mutational burdens, and tissue microenvironments.

Melody Chang, RPh, MBA, BCOP, explains how American Oncology Network leveraged its experience with the Oncology Care Model to address challenges when adopting the Enhanced Oncology Model.

The overall survival data were immature at the primary analysis of the study.

Diagnosing anemia, a serious and common complication of patients with myelofibrosis, could be made easier with the use of red cell distribution width assessment.

The supplemental new drug application is based on objective response rate and duration of response results from a phase 2 study that assessed the efficacy and safety of belzutifan.

This marks the first US biologic license application filing acceptance for a biosimilar candidate to golimumab.

As lung cancer cases rise, there is a significant need for therapeutic options that meet the challenges and needs of individual patients.

Data indicates fedratinib’s role as an effective second-line treatment in patients with myelofibrosis who have been previously treated with a JAK inhibitor, such as ruxolitinib, though more research is necessary.

MB-105 is a first-in-class CD5-targeted chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory CD5-positive T-cell lymphoma.

Isatuximab is a CD38-targeting monoclonal antibody that has demonstrated significant clinical success in improving minimal residual disease rates and progression-free survival.

The authors note that transferrin saturation levels may be a modifiable risk factor of chronic kidney disease (CKD) progression and all-cause mortality.

Gender-affirming care and inclusive practices are essential for health equity.

In 2025, medically integrated dispensing pharmacies face significant challenges, including low reimbursements, restrictive pharmacy benefit manager practices, complex therapies, regulatory barriers such as the Stark delivery law, and the Inflation Reduction Act's financial implications, necessitating urgent advocacy, reform, and collaboration to sustain equitable, patient-centered cancer care.

Pharmacists can have informed discussions with patients about the importance of adherence to tuberculosis (TB) treatment regimens, especially for patients with active TB.

The authors note that this may cause disruptions in the metabolic stability of lipid processing and storage, impacting the liver and accelerating damaging adaptative responses.

Endocrine therapy in combination with CDK4/6 inhibitors improves patients’ outcomes, but many still become treatment resistant.

Pharmacist-led interventions significantly improve antibiotic prescribing practices, optimize therapy, and improve patient outcomes.

The trial meets one of the study’s dual primary endpoints of progression-free survival, but did not meet its other primary endpoint of overall survival.

Fractyl Health also reports progress from the REMAIN-1 study evaluating weight management after discontinuing a GLP-1.

This case study underscores the critical importance of pharmacists who can provide comprehensive consideration and exploration of the appropriate treatment plan.

Challenges include therapy gaps, nonadherence, and fragmented care.

The antibody-drug conjugate shows efficacy in reducing disease progression risk and increasing progression-free survival in patients with HR+, HER2-low, or HER2-ultralow metastatic breast cancer.